$HUM

Humana Is Dropping Plans That Cover 600,000 Medicare Members in 2027. The Letters Arrive in September.

Humana (NYSE: HUM) said it will exit Medicare Advantage plans covering about 600,000 members in 2027, with letters to be sent in September, according to its July 29, 2026 earnings call. The company expects to recapture about 40% of the volume. Affected members may have a 63-day Medigap guaranteed-issue window after coverage ends.

Original reporting
Published Aug 14, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana Is Dropping Plans That Cover 600,000 Medicare Members in 2027. The Letters Arrive in September. — source image
Decision brief

The 30-second read

$HUMBearishLow
01

Why it matters

For affected members, the notice triggers a guaranteed-issue Medigap window and multiple enrollment periods, which can increase switching and churn. For Humana, it signals deliberate plan exits and creates uncertainty around 2027 membership mix and retention economics.

02

Market read

Traders may reassess HUM’s 2027 membership retention and churn assumptions, but the core disclosure is tied to a prior earnings call rather than a new filing or print.

03

What to watch

Member exits may be concentrated in specific plans/regions not detailed here, and Medigap guaranteed-issue windows could shift switching behavior in ways that are hard to translate into near-term financials.

Relevance 4/10Novelty 4/10Timing: letters to impacted members expected in September, ahead of Oct 15 AEP

Background

The article explains that Humana will send termination notices in September for certain Medicare Advantage plans that will not be offered in 2027.

Company-level read

Ticker impact

$HUMBearishMedium confidence
Context

Humana confirmed on its July 29, 2026 earnings call that Medicare Advantage plan exits will affect about 600,000 members in 2027.

Expected impact

Moderately negative bias for HUM as traders price higher churn and uncertainty around recapture rates into 2027.

Evidence & confidence

The article provides a concrete scope (600,000 members, ~8% of MA base) and timing (letters in September, coverage ends Dec 31, 2026), which can affect expectations for 2027 membership and profitability. However, it is framed as previously confirmed on an earnings call, limiting incremental surprise.

Market effects

Highlights Medicare Advantage plan nonrenewal mechanics and potential churn dynamics that could influence how investors underwrite MA member retention across peers.

No specific geography beyond general Medigap rules; limited direct regional read-through.

Primarily US Medicare Advantage policy and enrollment mechanics; limited global spillover.

Counterpoint

Humana expects to recapture a significant portion of the exited volume (about 40% based on its 2025 experience), which could blunt earnings impact if recapture holds.

Key entities

  • Humana

    Medicare Advantage insurer exiting plans affecting ~600,000 members in 2027, with letters arriving in September.

  • Celeste Mellet

    Humana CFO quoted confirming the expected member impact on the July 29, 2026 earnings call.

  • CMS Annual Notice of Change

    Deadline that requires plans to notify members by September 30, referenced as the trigger for the letters.

Related articles

Med

Glenmark USA Agrees to USD 15.28 Mn Settlement With Humana Over Generic Drug Antitrust Claims

Glenmark Pharmaceuticals said its U.S. subsidiary, Glenmark USA, agreed to settle with Humana Inc. for $15.28 million, including interest, to resolve antitrust and consumer protection claims over alleged generic drug price-fixing and market allocation. Glenmark USA denies all allegations. The company said the amount is already provided for in its financials and expects no significant financial impact.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.

MedAI 8/10

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

Glenmark Pharmaceuticals Ltd said its US unit, Glenmark Pharmaceuticals Inc., agreed to pay Humana Inc. $15.28 million to settle antitrust litigation over alleged price-fixing and market allocation in generic drugs. Glenmark said it denies all allegations and the settlement is not an admission of liability. The payment is in two installments and already provided for in its financials.